These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 16477587)
61. [Treatment research of intermediate severity depression: what is useful for the routine patient?]. MMW Fortschr Med; 2012 Feb; 154(2):69. PubMed ID: 22352257 [No Abstract] [Full Text] [Related]
63. Transient citalopram-induced auditory hallucinations in a patient with Parkinson's disease and depression. Wand AP Aust N Z J Psychiatry; 2012 Feb; 46(2):178. PubMed ID: 22311539 [No Abstract] [Full Text] [Related]
64. Suggested early onset of true action of antidepressant drugs may be artefactual: a heuristic study. Parker G; Paterson A; Blanch B Int Clin Psychopharmacol; 2013 Jan; 28(1):29-32. PubMed ID: 23232755 [TBL] [Abstract][Full Text] [Related]
65. Effectiveness and tolerability of citalopram for the treatment of depression and anxiety disorders in children and adolescents: an open-label study. Schirman S; Kronenberg S; Apter A; Brent D; Melhem N; Pick N; Carmel M; Frisch A; Weizman A; Gothelf D J Neural Transm (Vienna); 2010 Jan; 117(1):139-45. PubMed ID: 19851705 [TBL] [Abstract][Full Text] [Related]
66. Rhabdomyolysis after escitalopram treatment in a young adult with melancholic depression. Lecardeur L; Lefebvre A; Meunier-Cussac S J Clin Psychopharmacol; 2015 Feb; 35(1):108-9. PubMed ID: 25360882 [No Abstract] [Full Text] [Related]
67. Brief report: citalopram in child and adolescent depression with anxiety. Schaller JL; Behar D MedGenMed; 2001 Oct; 3(5):1. PubMed ID: 11698908 [No Abstract] [Full Text] [Related]
68. Cognitive improvement after treatment of depressive symptoms in the acute phase of stroke. Simis S; Nitrini R Arq Neuropsiquiatr; 2006 Jun; 64(2B):412-7. PubMed ID: 16917611 [TBL] [Abstract][Full Text] [Related]
69. Clinical development of citalopram. Willetts J; Lippa A; Beer B J Clin Psychopharmacol; 1999 Oct; 19(5 Suppl 1):36S-46S. PubMed ID: 10507507 [No Abstract] [Full Text] [Related]
70. Additional intranasal oxytocin to escitalopram improves depressive symptoms in resistant depression: an open trial. Scantamburlo G; Hansenne M; Geenen V; Legros JJ; Ansseau M Eur Psychiatry; 2015 Jan; 30(1):65-8. PubMed ID: 25282363 [TBL] [Abstract][Full Text] [Related]
71. Escitalopram (lexapro) for depression. Med Lett Drugs Ther; 2002 Sep; 44(1140):83-4. PubMed ID: 12360121 [No Abstract] [Full Text] [Related]
72. Escitalopram oxalate (Lexapro)-induced acneiform eruption. Khanna S; Chirinos RE; Venna S J Am Acad Dermatol; 2012 Dec; 67(6):e261-3. PubMed ID: 23158626 [No Abstract] [Full Text] [Related]
77. The preclinical observation that escitalopram possesses a faster time to onset of efficacy than citalopram. Håkanson R Pharmacol Toxicol; 2002 Jan; 90(1):3-4. PubMed ID: 12005110 [No Abstract] [Full Text] [Related]
78. Renal failure in a depressed adolescent on escitalopram. Miriyala K; Coffey B J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):405-8. PubMed ID: 18759653 [No Abstract] [Full Text] [Related]
79. The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. Mohs RC; Rosen WG; Davis KL Psychopharmacol Bull; 1983; 19(3):448-50. PubMed ID: 6635122 [No Abstract] [Full Text] [Related]
80. Major and minor depression in Alzheimer's disease: prevalence and impact. Lyketsos CG; Steele C; Baker L; Galik E; Kopunek S; Steinberg M; Warren A J Neuropsychiatry Clin Neurosci; 1997; 9(4):556-61. PubMed ID: 9447496 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]